Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pauillac covers the Healthcare sector, focusing on stocks such as Sanofi, Formycon AG, and COSMO Pharmaceuticals N.V.. According to TipRanks, Pauillac has an average return of 11.7% and a 48.15% success rate on recommended stocks.
In addition to Kepler Capital , Sandoz Group Ltd also received a Buy from Barclays's Emily Field in a report issued yesterday. However, on the same day, Jefferies downgraded Sandoz Group Ltd (Other OTC: SDZXF) to a Hold.
SDZXF market cap is currently $24.67B and has a P/E ratio of 107.75.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
‘Don't Go Bargain Hunting,' Says Top Investor About UnitedHealth Stock
UnitedHealth (NYSE:UNH) stock may have sunk like a stone – down 50% since the start of the year – yet the chance to buy a longtime industry leader at bargain-basement prices is hard for many investors to ignore. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That optimism took another blow with the latest Q2 earnings release. While UnitedHealth did bring in $112 billion in revenues – a 13% year-over-year increase – earnings proved far less encouraging. The company acknowledged its 2025 pricing assumptions were badly off, underestimating actual medical costs by $6.5 billion. It's a shortfall that didn't exactly take everyone by surprise. Many investors saw the losses coming – including one top investor, known by the pseudonym JR Research, who's baffled that others didn't see it coming. 'Please don't tell me some of you went to catch the falling knife UnitedHealth Group Incorporated before the healthcare leader reported its Q2 earnings scorecard,' pleads the 5-star investor, who is among the very top 1% of TipRanks' stock pros. JR explains that there are plenty of structural issues that are combining to make UNH's comeback journey ahead 'arduous' indeed. These include past execution steps, the misguided pricing expectations, and much higher medical utilization ratios. Moreover, the vast reduction in earnings is a concrete example – from an EPS of $29 to $30 all the way down to $16 for 2025 – that there will be no 'magical quick fixes' for UNH. And yet, there is a silver lining for investors, as the massive drop in value has decreased UNH's Forward Price-to-Earnings ratio to 13.7x, which is some 20% less than the healthcare median. JR concedes that patient, long-term holders might still find value in sticking around. That being said, with investor confidence in the dumps and a forward guidance that's not exactly inspiring, JR thinks this is one to avoid. 'I'm still trying to grapple with why investors would find the prospect of catching the falling knife on UNH appealing at all,' concludes JR Research, who is giving UNH a Hold (i.e. Neutral) rating. To watch JR Research's track record, click here) Wall Street, on the other hand, isn't ready to abandon UNH. With 18 Buy ratings far outpacing 3 Holds and 2 Sells, UNH enjoys a Moderate Buy consensus rating. Its 12-month average price target of $313.68 implies a 25% potential upside from current levels. (See UNH stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
3 hours ago
- Business Insider
‘Don't Make This Mistake,' Says Investor About Nvidia Stock
Nvidia (NASDAQ:NVDA) stock has seen no shortage of (mostly positive) news over the past few months, prompting some to wonder if it's time to follow the old market adage: 'Buy the rumor, sell the news.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That temptation is understandable. The lifting of export restrictions to China, billions in confirmed hyperscaler capex spending, and sovereign deals across the Middle East and Europe have all powered a 94% surge from April's lows. With such a strong rally already in the books, attention now turns to whether the upcoming Q2 FY 2026 earnings report, set for August 27, will justify the optimism – or reveal that expectations have run too far ahead. Investor Bohdan Kucheriavyi thinks the latter concern is misplaced. Selling now, he argues, would be a big mistake. 'Even after the latest rally, Nvidia's stock remains undervalued,' the 5-star investor says, pointing to catalysts that, in his view, still have plenty of runway. For starters, the return of Chinese sales should add meaningful tailwinds – and Kucheriavyi believes some of those gains may already be reflected in the quarter that just ended. The investor also notes that key ecosystem partners like ASML, TSMC, and SK Hynix have all posted robust results recently, reinforcing expectations for Nvidia's own strong performance. But his bullish stance isn't just about Q2. Looking further out, Kucheriavyi sees rising EBIT margins as Blackwell-driven profits start rolling in, creating another layer of growth beyond the China boost. According to his modeling, Nvidia could be pulling in roughly $200 billion in revenue by FY26. For this year alone, Kucheriavyi projects about $15 billion in additional sales – the exact amount analysts once assumed Nvidia would lose when the H20 ban first hit. With those restrictions now lifted, the investor sees a path to stronger-than-expected results, sustained double-digit revenue growth, and potentially even greater upside if the U.S. eventually allows sales of Nvidia's most advanced AI chips to China. Put together, Kucheriavyi believes these factors give NVDA's share price room to keep climbing. While nothing is certain, Kucheriavyi is putting his money where his mouth is. 'I recently bought more of Nvidia's shares, as I continue to consider them a solid investment,' emphasizes Kucheriavyi, who rates NVDA a Buy. (To watch Bohdan Kucheriavyi's track record, click here) Wall Street largely agrees. NVDA enjoys a Strong Buy consensus rating, backed by 34 Buy recommendations against just 3 Holds and a single Sell. The 12-month average price target sits at $186.24 – only modestly above current levels, but history suggests the market may still be underestimating what comes next. (See NVDA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Business Insider
4 hours ago
- Business Insider
‘Take the Plunge,' Says Top Investor About Tesla Stock
Tesla (NASDAQ:TSLA) stock is something of a Rorschach test, reflecting each investor's own hopes, doubts, and fears about the company and the market. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Are you a nuts-and-bolts, blue chip investor, interested only in the fundamental metrics of established companies that you can see and feel? Or, are you more of a risk taker, ready to buy into startup visions of grandeur? Both mindsets find fertile ground in Tesla – one reason the stock elicits such a wide range of emotions. And in 2025, the tug-of-war between the two narratives has been unfolding in real time. For instance, CEO Elon Musk's falling popularity earlier this year weighed heavily on global EV sales, sending the stock lower in the first half. Yet, the mood has shifted in recent months, as investors refocus on Musk's ambitions in self-driving, AI, and robotics – areas many believe could be Tesla's next trillion-dollar growth engine. That belief is shared by top investor James Foord, who is ready to take the plunge in what he calls a 'trillion-dollar startup.' 'Tesla is no longer just an EV company – it's an AI & robotics startup in disguise,' says the 5-star investor, who is among the top 2% of TipRanks' stock pros. Foord isn't blind to the near-term challenges, from tariff concerns to the loss of the $7,500 consumer tax credit, which have pressured operating margins. But the investor argues that the real story lies in the opportunities highlighted in Tesla's Q2 2025 earnings. 'The really important news is this: Tesla rolled out robotaxi operations in Austin, posted record profits in its energy division, (and is) targeting a massive rollout of its Optimus 3 over the coming years,' Foord asserts. In Foord's view, each of these segments holds billion-dollar potential. Energy remains Tesla's 'most overlooked business,' now delivering record profits. The Cybercab project could redefine ridesharing, taxis, and even personal car ownership. And with plans to produce 1 million Optimus 3 humanoid robots in the next five years, Tesla is reaching for an entirely new frontier. Even if some of these goals fall short, Foord believes the upside justifies the gamble. 'Elon shoots for the moon, and while he often misses, he still lands somewhere no one has been before. Tesla is a wild card, but it's a bet worth taking,' concludes Foord, who rates TSLA shares a Buy. (To watch James Foord's track record, click here) Of course, not everyone shares Foord's enthusiasm. Wall Street's view on TSLA remains sharply divided, with 13 Buys, 15 Holds, and 8 Sells, giving the stock a consensus Hold (i.e., Neutral) rating. The 12-month average price target of $305.37 suggests ~7% downside from current levels (See TSLA stock forecast). To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
